Safeguard Scientifics Inc. (SFE) Trading Down 4.1%
Safeguard Scientifics Inc. (NYSE:SFE) shares dropped 4.1% during mid-day trading on Friday . The company traded as low as $12.73 and last traded at $12.77, with a volume of 52,784 shares. The stock had previously closed at $13.31.
Separately, Zacks Investment Research raised shares of Safeguard Scientifics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Tuesday, June 14th.
The stock has a 50-day moving average price of $12.43 and a 200-day moving average price of $12.90. The company’s market capitalization is $260.38 million.
Safeguard Scientifics (NYSE:SFE) last announced its quarterly earnings data on Thursday, July 28th. The company reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.45. During the same quarter last year, the firm posted ($0.91) earnings per share. Equities analysts expect that Safeguard Scientifics Inc. will post ($0.74) EPS for the current year.
A hedge fund recently raised its stake in Safeguard Scientifics stock. Bank of Montreal Can raised its position in shares of Safeguard Scientifics Inc. (NYSE:SFE) by 3.7% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 542,390 shares of the company’s stock after buying an additional 19,168 shares during the period. Bank of Montreal Can owned about 2.63% of Safeguard Scientifics worth $7,870,000 as of its most recent SEC filing.
Safeguard Scientifics, Inc provides capital, as well as strategic, operational and management resources to growth-stage businesses. The Company participates in early- and growth-stage financings. The Company operates through two segments: Healthcare and Technology. The Healthcare segment’s companies focuses principally on medical technology (MedTech), including diagnostics and devices, and healthcare technology (HealthTech).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.